Press Releases
All Releases
 |
Spectrum Pharmaceuticals to Participate at the RBC Capital Markets Healthcare Conference Panel on Wednesday, March 3rd in New York City
Feb 25, 2010
|
21.1 KB |
|
| |
IRVINE, Calif., Feb 25, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage
biotechnology company with a focus in oncology, announced today that
Rajesh C. Shrotriya MD, Chairman, Chief Executive Officer, and President
of Spectrum Pharmaceuticals, will be a panelist on the topic of "Gear...
|
|
Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference in New York City on Tuesday, February 9th
Feb 5, 2010
|
21.1 KB |
|
| |
IRVINE, Calif., Feb 05, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage
biotechnology company with a focus in oncology, announced today that
Rajesh C. Shrotriya MD, Chairman, Chief Executive Officer, and President
of Spectrum Pharmaceuticals, will provide an overview of the Company'...
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Feb 2, 2010
|
27.0 KB |
|
| |
IRVINE, Calif, Feb 02, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that it has entered into a co-development and commercialization
agreement with TopoTarget A/S for Belinostat, a novel histone
deacetylase ...
|
|
Spectrum Pharmaceuticals Announces Receipt of $16 Million from Asian Partners Related to Apaziquone Collaboration Agreements Announced in November 2009
Jan 29, 2010
|
20.7 KB |
|
| |
IRVINE, Calif., Jan 29, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), announced today that it
has received $15 million from Nippon Kayaku in connection with the
collaboration agreement for apaziquone (EOquin(R)) announced on
November 10, 2009, and $1 million from Handok Pharmaceuticals announced
...
|
|
Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH) as It Continues to Prioritize Its Portfolio Strategy
Jan 27, 2010
|
21.0 KB |
|
| |
IRVINE, Calif., Jan 27, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that it is discontinuing development of ozarelix in benign prostatic
hypertrophy (BPH).
"While ozarelix is a potent GnRH antagonist, low-dose i...
|
|
Spectrum Pharmaceuticals Announces Results of FDA Meeting Regarding FUSILEV(R) sNDA under Review for Advanced Metastatic Colorectal Cancer
Jan 25, 2010
|
21.7 KB |
|
| |
IRVINE, Calif., Jan 25, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that it has met with the FDA regarding it's supplemental New Drug
Application (sNDA) for FUSILEV(R) (levoleucovorin) for
injection for t...
|
|
Spectrum Pharmaceuticals Completes Enrollment in Second of Two Phase 3 Pivotal Trials for Apaziquone in Non-Muscle Invasive Bladder Cancer
Jan 12, 2010
|
22.6 KB |
|
| |
IRVINE, Calif., Jan 12, 2010 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that the
second of two Phase 3 pivotal clinical trials of apaziquone has achieved
its enrollment target. The two trials enrolled more than 1600 patients
with non-muscle invasive bladder cancer. As per the collaboration
...
|
|
Zevalin(R) (Ibritumomab Tiuxetan) Demonstrated Activity in Several Investigational Phase 2 Trials Presented at the 51st Annual Meeting of the American Society of Hematology
Dec 11, 2009
|
36.2 KB |
|
| |
IRVINE, Calif., Dec 11, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial stage
biotechnology company with a primary focus in oncology, today announced
that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at
the 51st Annual Meeting of the American Society of Hematology (ASH), ...
|
|
Spectrum Pharmaceuticals Ranked among Orange County's Top Work Places for 2009
Dec 9, 2009
|
20.5 KB |
|
| |
IRVINE, Calif., Dec 09, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial stage
biotechnology company with a primary focus in oncology, today announced
that it has been ranked by the Orange County Register as one of Orange
County's Top Work Places for 2009.
"We are pleased to be recognized as o...
|
|
Spectrum Pharmaceuticals Engages Ernst & Young LLP as New Independent Registered Public Accounting Firm
Dec 8, 2009
|
20.7 KB |
|
| |
IRVINE, Calif., Dec 08, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM:SPPI) today announced that the Audit
Committee of the Board of Directors of the Company approved the
engagement of Ernst & Young, LLP (E&Y) as the Company's new independent
registered public accounting firm. As of December 3, 2009, the Company...
|
|
Spectrum Pharmaceuticals Announces ZEVALIN(R) Data Presentations at the 51st Annual Meeting of the American Society of Hematology in New Orleans
Dec 1, 2009
|
28.3 KB |
|
| |
IRVINE, Calif., Dec 01, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage
biotechnology company with a primary focus in oncology, today announced
that clinical data on ZEVALIN will be presented at the 51st Annual
Meeting of the American Society of Hematology (ASH), being held Decembe...
|
|
Spectrum Pharmaceuticals Announces Completion of Enrollment in One Apaziquone Phase 3 Pivotal Trial for Bladder Cancer Ahead of Schedule
Nov 30, 2009
|
22.3 KB |
|
| |
IRVINE, Calif., Nov 30, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI) today announced that one of
the two Phase 3 pivotal clinical trials of apaziquone has achieved its
enrollment target, having enrolled approximately 800 patients with
non-invasive bladder cancer. The second Phase 3 clinical trial of
...
|
|
Spectrum Pharmaceuticals and Handok Pharmaceuticals Announce Collaboration Agreement for Apaziquone in South Korea
Nov 23, 2009
|
26.4 KB |
|
| |
IRVINE, Calif., Nov 23, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage
biotechnology company with a primary focus in oncology, and Handok
Pharmaceuticals Co., Ltd., a fully integrated Korean pharmaceutical
company, today announced a collaboration for the development and
co...
|
|
Spectrum Pharmaceuticals Added to NASDAQ Biotechnology Index
Nov 16, 2009
|
21.5 KB |
|
| |
IRVINE, Calif., Nov 16, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM:SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that it has been selected for addition to the NASDAQ Biotechnology Index(R)
(Nasdaq: NBI). The Company is now a component of the NASDAQ
...
|
|
Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN(R) Sales up 80% over Third Quarter 2008
Nov 12, 2009
|
32.6 KB |
|
| |
IRVINE, Calif., Nov 12, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today reported
financial results for the third quarter ended September 30, 2009.
"During the quarter, we made significant progress toward stabilizing,
an...
|
|
Spectrum Pharmaceuticals and Nippon Kayaku Enter Collaboration Agreement for Apaziquone in Asian Territories
Nov 10, 2009
|
26.4 KB |
|
| |
IRVINE, Calif., Nov 10, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial stage
biotechnology company with a primary focus in oncology, and Nippon
Kayaku today announced an exclusive collaboration for the development
and commercialization of apaziquone in Asia. Apaziquone is an
ant...
|
|
Spectrum Pharmaceuticals Announces Date for Third Quarter 2009 Corporate Update and Pipeline Review Conference Call
Nov 6, 2009
|
20.8 KB |
|
| |
IRVINE, Calif., Nov 06, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a focus in oncology, today announced the date
and time for its third quarter 2009 corporate update and pipeline review
conference call.
Conference CallFriday, November 13, 2009 @
...
|
|
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Nov 3, 2009
|
23.4 KB |
|
| |
IRVINE, Calif., Nov 03, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that the Centers for Medicare & Medicaid Services (CMS) finalized a
policy to allow reimbursement for ZEVALIN(R) (ibritumomab
tiuxetan),...
|
|
Spectrum Pharmaceuticals to Present at the 2009 BIOCOM Investor Conference
Oct 26, 2009
|
19.8 KB |
|
| |
IRVINE, Calif., Oct 26, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a focus in oncology, announced today that an
overview of the Company's business strategy will be presented at the
2009 BIOCOM Investor Conference on Tuesday, October 27, 2009 at 9:30a...
|
|
Spectrum Pharmaceuticals, Inc. Ranked #22 Fastest Growing Company in North America on Deloitte's 2009 Technology Fast 500(TM)
Oct 20, 2009
|
23.3 KB |
|
| |
IRVINE, Calif., Oct 20, 2009 (BUSINESS WIRE) -- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage
biotechnology company with a primary focus in oncology, today announced
that it ranked #22 on Technology Fast 500(TM), Deloitte LLP's
ranking of 500 of the fastest growing technology, media,
telecommunication...
|
|
|
=add release to Briefcase |
| Stock Information |
NASDAQ:SPPI
$5.05
- 0.04
|
Mar 10, 2010
12:47 PM ET |
Quotes delayed at least 20 minutes.
Information provided by eSignal.
| Search Investor Relations |
|
|
